Market Summary
USD2.02-0.06
Market Closed-2.88%
FATE Stock Price
FATE RSI Chart
FATE Valuation
FATE Price/Sales (Trailing)
FATE Profitability
FATE Fundamentals
FATE Revenue
FATE Earnings
Price Action
52 Week Range
1.9923.96
(Low)(High)
Last 7 days
-18.4%
Last 30 days
-20.9%
Last 90 days
-58.9%
Trailing 12 Months
-90.5%
FATE Financial Health
FATE Investor Care
Historical Charts for Stock Metrics
Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
Get all data in R, Python etc through our Historical Stock Data APIs
Latest Insider Trading transactions for FATE
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
2023-08-18 | Dulac Edward J III | sold | -13,210 | 2.8 | -4,718 | chief financial officer |
2023-08-04 | Xu Yuan | sold | -2,344 | 3.71 | -632 | - |
2023-07-05 | Dulac Edward J III | sold | -25,029 | 4.83 | -5,182 | chief financial officer |
2023-07-05 | Powl Brian T. | sold | -18,769 | 4.87 | -3,854 | chief commercial officer |
2023-06-14 | Xu Yuan | sold | -19,306 | 5.58 | -3,460 | - |
2023-04-21 | Redmile Group, LLC | bought | 1,586,030 | 6.18 | 256,639 | - |
2023-04-20 | Redmile Group, LLC | bought | 119,800 | 5.99 | 20,000 | - |
2023-04-18 | Chu Yu-Waye | sold | -16,647 | 6.57491 | -2,532 | chief medical officer |
2023-04-14 | Redmile Group, LLC | sold | -32,075,500 | 5.84 | -5,492,380 | - |
2023-04-14 | Redmile Group, LLC | bought | 154,200 | 6.00 | 25,700 | - |
Which funds bought or sold FATE recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
2023-09-20 | BARCLAYS PLC | reduced | -4.34 | -574,000 | 2,281,000 | -% |
2023-08-22 | VIRGINIA RETIREMENT SYSTEMS ET AL | added | 86.67 | 57,336 | 159,936 | -% |
2023-08-22 | Asset Dedication, LLC | unchanged | - | - | - | -% |
2023-08-21 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | reduced | -1.94 | -102,416 | 462,996 | -% |
2023-08-21 | OSAIC HOLDINGS, INC. | reduced | -3.34 | -7,063 | 30,257 | -% |
2023-08-17 | Coppell Advisory Solutions LLC | new | - | 42,375 | 42,375 | 0.01% |
2023-08-16 | Nuveen Asset Management, LLC | added | 30.89 | 116,312 | 1,374,310 | -% |
2023-08-15 | COLONY GROUP LLC | unchanged | - | -22,000 | 114,000 | -% |
2023-08-15 | BENJAMIN F. EDWARDS & COMPANY, INC. | unchanged | - | -1,000 | 2,000 | -% |
2023-08-15 | ALLIANCEBERNSTEIN L.P. | added | 24.88 | 24,879 | 605,139 | -% |
Latest Funds Activity
Calls
Puts
Net Call Options
No. of Funds
Schedule 13G FIlings of Fate Therapeutics
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| May 10, 2023 | state street corp | 14.24% | 13,989,432 | SC 13G/A | |
| Apr 19, 2023 | redmile group, llc | 14.9% | 15,071,096 | SC 13D/A | |
| Mar 22, 2023 | millennium management llc | 1.7% | 1,696,431 | SC 13G | |
| Mar 10, 2023 | vanguard group inc | 10.12% | 9,936,042 | SC 13G/A | |
| Feb 13, 2023 | capital world investors | 5.8% | 5,591,517 | SC 13G | |
| Feb 09, 2023 | vanguard group inc | 8.20% | 7,972,551 | SC 13G/A | |
| Feb 03, 2023 | state street corp | 6.11% | 5,935,459 | SC 13G | |
| Jan 06, 2023 | blackrock inc. | 10.0% | 9,725,895 | SC 13G/A | |
| Feb 09, 2022 | ark investment management llc | 10.80% | 10,312,167 | SC 13G/A | |
| Feb 03, 2022 | blackrock inc. | 7.4% | 7,060,552 | SC 13G/A |
Recent SEC filings of Fate Therapeutics
View All Filings| Date Filed | Form Type | Document | |
|---|---|---|---|
| Sep 01, 2023 | 8-K | Current Report | |
| Aug 21, 2023 | 4 | Insider Trading | |
| Aug 18, 2023 | 144 | Notice of Insider Sale Intent | |
| Aug 08, 2023 | 8-K | Current Report | |
| Aug 08, 2023 | 10-Q | Quarterly Report | |
| Aug 07, 2023 | 4 | Insider Trading | |
| Aug 04, 2023 | 144 | Notice of Insider Sale Intent | |
| Jul 06, 2023 | 4 | Insider Trading | |
| Jul 06, 2023 | 4 | Insider Trading | |
| Jul 05, 2023 | 144 | Notice of Insider Sale Intent |
Peers (Alternatives to Fate Therapeutics)
View All Peers In Detail| Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|
| LARGE-CAP | ||||||||
AMGN | 143.9B | 26.6B | 4.09% | 19.43% | 18.04 | 5.41 | 0.75% | 21.34% |
GILD | 94.2B | 27.4B | -2.64% | 21.17% | 17.17 | 3.44 | -0.48% | 32.56% |
MRNA | 37.4B | 10.7B | -12.29% | -20.60% | 30.97 | 3.51 | -53.67% | -91.41% |
BIIB | 37.3B | 10.0B | -3.56% | 28.94% | 14.01 | 3.74 | -6.23% | 29.40% |
| MID-CAP | ||||||||
NBIX | 11.1B | 1.7B | 5.73% | 9.84% | 62.9 | 6.63 | 29.01% | 1345.90% |
BBIO | 4.3B | - | -8.76% | 177.74% | -7.34 | 48.33 | 54.84% | -12.96% |
DNLI | 3.0B | - | -4.47% | -19.12% | -23.53 | 37.44 | 122.90% | 54.78% |
BEAM | 1.8B | 80.2M | -0.86% | -51.14% | -5.62 | 22.95 | 42.17% | -39.82% |
| SMALL-CAP | ||||||||
RCUS | 1.4B | 121.2M | -17.40% | -25.98% | -4.84 | 11.47 | -70.36% | -531.73% |
REPL | 952.5M | 15.3M | -21.41% | 1.70% | -5.24 | 62.21 | 1090.59% | -36.57% |
NVAX | 670.5M | 1.6B | -9.19% | -65.19% | -1.14 | 0.42 | 23.74% | 60.24% |
FATE | 204.9M | - | -20.91% | -90.53% | -0.97 | 1.5 | 116.83% | 16.61% |
SGMO | 120.9M | - | -9.97% | -85.99% | -0.61 | 0.5 | 113.96% | -15.19% |
VXRT | 107.9M | 2.1M | -8.04% | -65.52% | -1.07 | 52.51 | 487.70% | -8.66% |
IBIO | 3.7M | - | -11.22% | -96.54% | -0.05 | 3.21 | - | -129.46% |
Fate Therapeutics News
Returns for FATE
Cumulative Returns on FATE
-6.8%
7-Year Cumulative Returns
-32.9%
5-Year Cumulative Returns
-62.0%
3-Year Cumulative Returns
Risks for FATE
What is the probability of a big loss on FATE?
100%
Probability that Fate Therapeutics stock will be more than 20% underwater in next one year
98.1%
Probability that Fate Therapeutics stock will be more than 30% underwater in next one year.
42.7%
Probability that Fate Therapeutics stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.
How does FATE drawdown profile look like?
Y-axis is the maximum loss one would have experienced if Fate Therapeutics was unfortunately bought at previous high price.
Drawdowns
Financials for Fate Therapeutics
Income Statement (Last 12 Months)
| Income Statement (Last 12 Months) | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Revenue | -100.0% | - | 136,866,000 | 96,300,000 | 69,013,000 | 68,257,000 | 63,120,000 | 55,846,000 | 54,675,000 | 48,008,000 | 40,061,000 | 31,434,000 | 18,340,000 | 13,211,000 | 10,563,000 | 10,680,000 | 9,539,000 | 8,136,000 | 6,346,000 | 4,740,000 | 4,106,000 | 4,106,000 |
| Operating Expenses | -9.6% | 361,217,000 | 399,377,000 | 404,686,000 | 382,362,000 | 349,838,000 | 308,371,000 | 272,840,000 | 235,686,000 | 205,883,000 | 179,864,000 | 159,519,000 | 142,104,000 | 132,607,000 | 125,336,000 | 111,407,000 | 97,929,000 | 86,099,000 | 79,830,000 | 71,832,000 | 66,701,000 | 60,349,000 |
| S&GA Expenses | 2.7% | 87,704,000 | 85,433,000 | 84,232,000 | 79,584,000 | 73,747,000 | 65,564,000 | 57,321,000 | 50,699,000 | 43,332,000 | 38,667,000 | 33,896,000 | 30,254,000 | 28,249,000 | 26,016,000 | 23,637,000 | 21,273,000 | 19,008,000 | 17,554,000 | 15,808,000 | 14,885,000 | 13,592,000 |
| R&D Expenses | -12.9% | 273,513,000 | 313,944,000 | 320,454,000 | 302,778,000 | 276,091,000 | 242,807,000 | 215,519,000 | 184,987,000 | 162,551,000 | 141,197,000 | 125,623,000 | 111,850,000 | 104,358,000 | 99,320,000 | 87,770,000 | 76,656,000 | 67,091,000 | 62,276,000 | 56,024,000 | 51,816,000 | 46,757,000 |
| Interest Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1,752,000 | 1,644,000 | 1,673,000 | 1,689,000 | 1,696,000 | 1,678,000 | 1,627,000 |
| Net Income | 9.9% | -211,599,000 | -234,949,000 | -281,721,000 | -294,046,000 | -253,754,000 | -232,782,000 | -212,151,000 | -196,617,000 | -211,993,000 | -184,932,000 | -173,387,000 | -148,578,000 | -116,503,000 | -111,909,000 | -98,149,000 | -85,874,000 | -76,047,000 | -72,223,000 | -66,598,000 | -63,068,000 | -56,970,000 |
| Net Income Margin | 100.0% | - | -1.72 | -2.93 | -4.26 | -3.72 | -3.69 | -3.80 | -3.60 | -4.42 | -4.62 | -5.52 | -8.10 | -8.82 | -10.59 | -9.19 | - | - | - | - | - | - |
| Free Cashflow | 100.0% | - | -241,145,000 | -283,774,000 | -290,370,000 | -274,757,000 | -257,194,000 | -213,574,000 | -147,848,000 | -131,425,000 | -47,495,000 | -44,161,000 | -49,350,000 | -38,765,000 | -99,074,000 | -90,570,000 | - | - | - | - | - | - |
Balance Sheet(In Millions)
| Balance Sheet | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Assets | -7.2% | 585 | 630 | 706 | 749 | 807 | 858 | 921 | 985 | 1,016 | 1,046 | 622 | 626 | 654 | 322 | 302 | 340 | 200 | 221 | 213 | 220 | 83.00 |
| Current Assets | -10.4% | 392 | 438 | 502 | 535 | 599 | 599 | 633 | 694 | 713 | 804 | 494 | 497 | 540 | 208 | 227 | 306 | 165 | 186 | 205 | 214 | 80.00 |
| Cash Equivalents | 11.4% | 47.00 | 42.00 | 61.00 | 82.00 | 55.00 | 65.00 | 134 | 129 | 77.00 | 106 | 167 | 349 | 433 | 83.00 | 100 | 250 | 71.00 | 183 | 191 | 183 | 36.00 |
| Net PPE | -2.1% | 106 | 109 | 110 | 109 | 103 | 98.00 | 92.00 | 75.00 | 59.00 | 48.00 | 32.00 | 21.00 | 16.00 | 12.00 | 11.00 | 10.00 | 9.00 | 8.00 | 5.00 | 4.00 | 3.00 |
| Current Liabilities | -8.1% | 45.00 | 49.00 | 114 | 104 | 92.00 | 78.00 | 81.00 | 92.00 | 106 | 95.00 | 86.00 | 54.00 | 45.00 | 25.00 | 28.00 | 41.00 | 29.00 | 29.00 | 27.00 | 23.00 | 16.00 |
| LT Debt, Current | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 14.00 | 5.00 | 4.00 | 2.00 | 3.00 | 2.00 |
| LT Debt, Non Current | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 9.00 | 11.00 | 12.00 | 12.00 | 13.00 |
| Shareholder's Equity | -8.3% | 438 | 477 | 484 | 518 | 580 | 633 | 679 | 730 | 752 | 790 | 384 | 424 | 474 | 219 | 245 | 268 | 128 | 146 | 160 | 174 | 52.00 |
| Retained Earnings | -4.9% | -1,122 | -1,069 | -1,050 | -994 | -910 | -834 | -769 | -700 | -657 | -602 | -556 | -503 | -445 | -417 | -383 | -355 | -328 | -305 | -285 | -269 | -252 |
| Additional Paid-In Capital | 0.8% | 1,561 | 1,548 | 1,536 | 1,516 | 1,495 | 1,471 | 1,449 | 1,431 | 1,409 | 1,392 | 941 | 928 | 919 | 636 | 628 | 623 | 456 | 451 | 446 | 443 | 304 |
| Shares Outstanding | 0.3% | 99.00 | 98.00 | 97.00 | 97.00 | 97.00 | 96.00 | 96.00 | 95.00 | 94.00 | 93.00 | 88.00 | 81.00 | 78.00 | 76.00 | 68.00 | 67.00 | 65.00 | 65.00 | 56.00 | 53.00 | 53.00 |
Cashflow (Last 12 Months)(In Millions)
| Cashflow (Last 12 Months) | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Cashflow From Operations | 11.6% | -187 | -212 | -248 | -243 | -221 | -200 | -162 | -113 | -110 | -39.65 | -39.23 | -44.10 | -33.20 | -92.35 | -83.17 | -68.66 | -52.38 | -43.59 | -38.65 | -38.35 | -44.56 |
| Share Based Compensation | -10.9% | 63.00 | 70.00 | 79.00 | 74.00 | 68.00 | 61.00 | 54.00 | 49.00 | 43.00 | 37.00 | 31.00 | 27.00 | 23.00 | 20.00 | 17.00 | 15.00 | 12.00 | 9.00 | 6.00 | 5.00 | 5.00 |
| Cashflow From Investing | -3.9% | 176 | 183 | 167 | 185 | 182 | 141 | -324 | -561 | -693 | -656 | -161 | -105 | -15.14 | -142 | -157 | -30.55 | -53.56 | 52.00 | -0.46 | -3.64 | -3.28 |
| Cashflow From Financing | -50.6% | 3.00 | 7.00 | 9.00 | 11.00 | 18.00 | 18.00 | 453 | 455 | 448 | 719 | 283 | 264 | 425 | 150 | 150 | 166 | 141 | 142 | 141 | 182 | 53.00 |
FATE Income Statement
2023-06-30Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|
Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | |
| Income Statement [Abstract] | ||||
| Collaboration revenue | $ 933 | $ 18,549 | $ 59,913 | $ 36,963 |
| Type of Revenue [Extensible List] | us-gaap:LicenseMember | us-gaap:LicenseMember | us-gaap:LicenseMember | us-gaap:LicenseMember |
| Operating expenses: | ||||
| Research and development | $ 40,876 | $ 81,307 | $ 106,505 | $ 153,446 |
| General and administrative | 22,622 | 20,351 | 44,565 | 41,093 |
| Total operating expenses | 63,498 | 101,658 | 151,070 | 194,539 |
| Loss from operations | (62,565) | (83,109) | (91,157) | (157,576) |
| Other income: | ||||
| Interest income | 4,381 | 757 | 8,075 | 1,175 |
| Change in fair value of stock price appreciation milestones | 393 | 5,881 | 2,111 | 14,240 |
| Other income | 5,036 | 366 | 9,335 | 366 |
| Total other income | 9,810 | 7,004 | 19,521 | 15,781 |
| Net loss | (52,755) | (76,105) | (71,636) | (141,795) |
| Other comprehensive income (loss): | ||||
| Unrealized gain (loss) on available-for-sale securities, net | 59 | (531) | 1,267 | (2,619) |
| Comprehensive loss | $ (52,696) | $ (76,636) | $ (70,369) | $ (144,414) |
| Net loss per common share, basic | $ (0.54) | $ (0.79) | $ (0.73) | $ (1.47) |
| Net loss per common share, diluted | $ (0.54) | $ (0.79) | $ (0.73) | $ (1.47) |
| Weighted-average common shares used to compute, basic net loss per share | 98,400,355 | 96,704,413 | 98,228,476 | 96,524,968 |
| Weighted-average common shares used to compute diluted net loss per share | 98,400,355 | 96,704,413 | 98,228,476 | 96,524,968 |
FATE Balance Sheet
2023-06-30Condensed Consolidated Balance Sheets - USD ($) $ in Thousands | Jun. 30, 2023 | Dec. 31, 2022 |
|---|---|---|
| Current assets: | ||
| Cash and cash equivalents | $ 46,802 | $ 61,333 |
| Accounts receivable | 2,833 | 38,480 |
| Short-term investments and related maturity receivables | 331,133 | 374,894 |
| Prepaid expenses and other current assets | 11,414 | 27,367 |
| Total current assets | 392,182 | 502,074 |
| Long-term investments | 7,291 | 4,942 |
| Property and equipment, net | 106,331 | 110,020 |
| Operating lease right-of-use assets | 63,743 | 66,069 |
| Restricted cash | 15,177 | 15,227 |
| Collaboration contract assets | 0 | 7,196 |
| Other assets | 33 | 33 |
| Total assets | 584,757 | 705,561 |
| Current liabilities: | ||
| Accounts payable | 7,506 | 8,265 |
| Accrued expenses | 29,469 | 53,932 |
| CIRM award liability, current portion | 0 | 4,000 |
| Deferred revenue | 1,929 | 42,226 |
| Operating lease liabilities, current portion | 5,786 | 5,628 |
| Total current liabilities | 44,690 | 114,051 |
| Operating lease liabilities, net of current portion | 100,562 | 103,710 |
| Stock price appreciation milestones | 1,750 | 3,861 |
| Commitments and contingencies | ||
| Stockholders’ equity: | ||
| Preferred stock, $0.001 par value; authorized shares-5,000,000 at June 30, 2023 and December 31, 2022; Class A Convertible Preferred shares issued and outstanding-2,761,108 at June 30, 2023 and 2,794,549 December 31, 2022 | 3 | 3 |
| Common stock, $0.001 par value; authorized shares-250,000,000 at June 30, 2023 and December 31, 2022; issued and outstanding-98,522,718 at June 30, 2023 and 97,294,917 at December 31, 2022 | 99 | 97 |
| Additional paid-in capital | 1,560,680 | 1,536,497 |
| Accumulated other comprehensive loss | (587) | (1,854) |
| Accumulated deficit | (1,122,440) | (1,050,804) |
| Total stockholders’ equity | 437,755 | 483,939 |
| Total liabilities and stockholders’ equity | $ 584,757 | $ 705,561 |
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid tumors; and FT500 for the treatment of advanced solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies; and a collaboration and option agreement with Janssen Biotech, Inc. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.